搜尋結果
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.{br}{br}TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites.
台微體子公司公佈瑞德西韋先驅活性物新劑型之策略 於科學大會發表ISPM21及ISPM19治療新冠肺炎之優勢
2020年8月14日 · TLC19 運用既有台微體獨家微脂體包覆技術平台，以口服 HCQ 近百分之一的劑量改良成吸入劑型，直接傳遞至上呼吸道及肺部目標組織。
TLC599 乃台微體獨家「 BioSeizer ® 」長效緩釋配方之地塞米松磷酸鈉藥物，一針即可快速且持續緩解關節炎帶來之疼痛。 TLC599的脂質配方在臨床前研究中，即使重複給藥，也未觀察到蛋白聚醣損失。
We encourage you to read the privacy policy of every website you visit. {br} {br}Click “STAY” to return to tlcbio.com or “CONTINUE” to proceed. This privacy policy (“policy”) sets out how TLC uses and protects any information that you give to us.
一、發言人及代理發言人姓名、職稱、聯絡電話及電子郵件信箱 發言人 代 理 發 言 人 姓名 曾雲龍 施雪芳 周步朗 職稱 副 ...
Osteoarthritis (OA) is a joint disorder involving the degeneration of the articular cartilage in knee. OA leads to inflammation of the soft tissue and bony structures of the joint. This condition grows more severe over time and leads to progressive thinning of articular cartilage.
Founded in 1997 by renowned liposome scientist Dr. Keelung Hong, TLC BioSciences is advancing innovative lipid-based drug delivery technologies. As a researcher, Dr. Hong worked alongside Dr. Demetrios Papahadjopoulos, the pioneering father of liposome research, and was heavily involved in the development of the first FDA-approved liposomal ...
Pioneering Orthopedic & Pain Solutions to Fulfill Unmet Medical Needs. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®).
Gene Therapy TLC BioSciences is at the forefront of gene therapy, with our cutting-edge LNP platform delivering genetic treatments with precision. Our therapies, like TLC501 and TLC502, target orthopedic disorders at their root, offering lasting solutions. We're ...
